Biotech Values

[DewDiligence]

JNJ issues boilerplate response to Xarelto CRL in ACS, but it doesn’t ring true, IMO:

http://finance.yahoo.com/news/fda-issues-complete-response-letters-130000012.html

"We remain committed to providing patients who have suffered from acute coronary syndrome with additional protection against stent thrombosis and secondary life-threatening cardiovascular events," said Paul Burton, M.D., Ph.D., Vice President, Clinical Development, Janssen Research & Development. "We are evaluating the contents of the [CRL] letters and will determine the appropriate next steps."

I think Xarelto for ACS is dead, period.